2Sheppard P,Kindsvogel W,Xu W,et al.IL-28,IL-29 and their class Ⅱ cytokine receptor IL-28R[J].Nat Immunol,2003,4(1):63-68.
3Kotenko SV,Gallagher G,Baurin VV,et al.IFN-λs mediate antiviral protection through a distinct class Ⅱ cytokine receptor complex[J].Nat Immunol,2003,4(1):69-77.
4Coccia EM,Severa M,Giacomini E,et al.Viral infection and Toll-like receptor agonists induce a differential expression of type Ⅰ and λ interferon as in human plasmacytoid and monocyte-derived dendritic cells[J].Eur J Immunol,2004,34(3):796-805.
5Gautier G,Humbert M,Deauvieau F,et al.A type Ⅰ interferon autocrine-paracrine loop is involved in Toll-like receptor-induced interleukin-12p70 secretion by dendritic cells[J].J Exp Med,2005,201(9):1435-1446.
7Brand S,Zitzmann K,Dambacher J,et al.SOCS-1 inhibits expression of the antiviral proteins 2′,5′-OAS and MxA induced by the novel interferon-lambdas IL-28A and IL-29[J].Biochem Biophys Res Commun,2005,331(2):543-548.
8Meager A,Visvalingam K,Dilger P,et al.Biological activity of interleukins-28 and -29:Comparison with type Ⅰ interferons[J].Cytokine,2005,31(2):109-118.
9Dumoutier L,Tounsi A,Michiels T,et al.Role of the interleukin (IL)-28 receptor tyrosine residues for antiviral and antiproliferative activity of IL-29/interferon-lambda 1:Similarities with type Ⅰ interferon signaling[J].J Biol Chem,2004,279(31):32269-32274.
